GABA Therapeutics is spearheading the development of GRX-917, a groundbreaking drug candidate poised to address a wide array of neuropsychiatric, neurologic, and pain disorders. By stimulating the production of brain neurosteroids, this innovative medication holds promise for patients grappling with conditions such as generalized anxiety disorder, postpartum depression, and panic disorder, among others. As a company, our primary focus is on pioneering safe and effective treatments for central nervous system disorders, guided by our core values of social responsibility, integrity, empathy, and a commitment to excellence.

With upcoming Phase 2/3 studies on the horizon, GABA Therapeutics is dedicated to advancing the field of neurology and making a meaningful impact on the lives of individuals worldwide